A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone in the Treatment of Irritability Associated with Autism Spectrum Disorder in Pediatric Patients 5 to 17 Years of Age - NIL

Start Date12 Mar 2026

Sponsor / Collaborator

Intra-Cellular Therapies, Inc.

[+1]

NCT07369115

/ Not yet recruitingPhase 4IIT

Intra-Cellular Therapies, Inc. / "A Randomized, Double-blind, Placebo-controlled, Single Site Study to Evaluate the Efficacy of Lumateperone for the Treatment of Major Depressive Disorder (MDD) and Early Life Trauma in Adult Patients Aged 21 to 70 Years

The purpose of this clinical research study is to understand how effective and safe an investigational study drug called lumateperone is and whether it works to reduce the severity of depressive symptoms in adults with Major Depressive Disorder (MDD) and early life trauma. The main questions it aims to answer are:
Aim 1: To assess the efficacy of lumateperone 42 mg administered once daily compared with placebo in the treatment of patients with Major Depressive Disorder and early life abuse.
Aim 2: To assess neurocircuitry encoding of threat and reward learning as predictors of lumateperone response and as mechanisms of treatment action, and assess the change from pre-dose to post-dose of task-evoked brain activation.

Start Date01 Feb 2026

Sponsor / Collaborator

The University of Texas at Austin

CTR20254391

/ Active, not recruitingNot Applicable

甲苯磺酸卢美哌隆胶囊在空腹条件下的人体生物等效性研究

[Translation] Bioequivalence study of lumepimeperone tosylate capsules in humans under fasting conditions

主要研究目的研究空腹状态下单次口服受试制剂甲苯磺酸卢美哌隆胶囊与参比制剂甲苯磺酸卢美哌隆胶囊（CAPLYTA®）在健康成年受试者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的研究受试制剂甲苯磺酸卢美哌隆胶囊和参比制剂“CAPLYTA®”在健康受试者中的安全性。

[Translation]

Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation lumepirozoline tosylate capsules and the reference formulation lumepirozoline tosylate capsules (CAPLYTA®) in healthy adult subjects under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary Objective: To investigate the safety of the test formulation lumepirozoline tosylate capsules and the reference formulation CAPLYTA® in healthy subjects.

Start Date12 Jan 2026

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Lumateperone Tosylate

100 Translational Medicine associated with Lumateperone Tosylate

100 Patents (Medical) associated with Lumateperone Tosylate

138

Literatures (Medical) associated with Lumateperone Tosylate

01 Jul 2026·JOURNAL OF AFFECTIVE DISORDERS

The efficacy of lumateperone across symptoms of a major depressive episode with mixed features in patients with major depressive disorder and bipolar disorder: Post hoc analyses

Article

Author: Huo, Jason ; Kozauer, Susan G ; Yatham, Lakshmi N ; Durgam, Suresh ; Earley, Willie R

INTRODUCTION:

Current treatments for major depressive episodes may not resolve all symptoms, with residual symptoms predicting disease relapse, recurrence, and functional impairment. This post hoc analysis of Study 403 (NCT04285515), a randomized, double-blind, placebo-controlled trial in patients with major depressive disorder (MDD) or bipolar disorder presenting with a major depressive episode with mixed features, evaluated the breadth of efficacy of lumateperone 42 mg across depressive symptoms assessed by Montgomery-Åsberg Depression Rating Scale (MADRS) single item scores.

METHODS:

Adults aged 18-75 years who met DSM-5 criteria for MDD or bipolar disorder with depressive episode with mixed features were randomized 1:1 to receive 6-week lumateperone 42 mg or placebo treatment.

RESULTS:

Among 383 patients in the modified intent-to-treat population, lumateperone significantly improved 9 out of 10 MADRS items, except Suicidal Thoughts, versus placebo at Day 43, with earliest significant improvements observed from Days 8-15. A significantly higher proportion of patients had reduced symptom severity with lumateperone versus placebo across a range of individual MADRS items. A smaller percentage of patients with moderate-to-severe baseline symptoms (MADRS score ≥4) continued to have item scores ≥4 at end of treatment with lumateperone compared with placebo across all individual MADRS items, except for the Suicidal Thoughts item. Young Mania Rating Scale Total score improved from baseline to Day 43 versus placebo, with fewer patients experiencing mania worsening.

CONCLUSION:

Lumateperone 42 mg improved a broad range of depressive symptoms in patients with MDD and bipolar depression with mixed features, supporting its therapeutic potential in these conditions.

01 Mar 2026·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study

Article

Author: Kozauer, Susan G. ; Davis, Robert E. ; Tohen, Mauricio ; Mates, Sharon ; Durgam, Suresh ; Chen, Changzheng

This 6-month open-label extension (OLE) period of a Phase 3 placebo-controlled study (NCT02600494) examined the safety of lumateperone in patients with bipolar I or bipolar II depression. Eligible patients completing the placebo-controlled period received lumateperone 42 mg once daily up to 175 days. The primary endpoint was safety and tolerability, assessed by adverse events (AEs) and clinical laboratory evaluations analyzed by imputing missing data using a last observation carried forward approach. The secondary endpoint was efficacy measured by Montgomery-Åsberg Depression Rating Scale (MADRS) total and Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) scores. Of 127 patients in the OLE, 58.3% completed treatment, and 42.5% experienced a drug-related treatment-emergent AE (TEAE); the most common TEAEs were headache (20.5%), dry mouth (11.8%), dizziness (10.2%), and nausea (10.2%). The majority (92%) of TEAEs were of mild or moderate severity. There were no notable changes in extrapyramidal symptom scores, cardiometabolic parameters, or body morphology. MADRS total score (mean change, −8.9, nominal P < 0.0001), CGI-BP-S total score (−2.3, nominal P < 0.0001), and CGI-BP-S depression subscore (−1.3, nominal P < 0.0001) improved over time, from baseline to Day 175. Overall, 6-month lumateperone 42 mg was generally well tolerated, and depressive symptoms based on MADRS total score and CGI-BP-S improved over time.

01 Mar 2026·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial

Article

Author: Chen, Changzheng ; Kozauer, Susan G. ; Mates, Sharon ; Correll, Christoph U. ; Davis, Robert E. ; Lakkis, Hassan D. ; Durgam, Suresh ; Vanover, Kimberly E.

This Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of lumateperone to treat bipolar depression. Patients (18–75 years) with bipolar I or bipolar II disorder experiencing a major depressive episode were randomized 1:1:1 to 6-week lumateperone 28 mg ( n = 183), lumateperone 42 mg ( n = 185), or placebo ( n = 186). Primary and key secondary endpoints were change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total score and time to first sustained response (≥50% reduction from baseline in MADRS Total score), respectively. Safety assessments included adverse events, extrapyramidal symptoms (EPS), laboratory evaluations, and vital signs. Neither dose of lumateperone achieved significant improvement vs. placebo ( P > 0.05) in the primary endpoint (MADRS Total score, least squares mean difference vs. placebo: 28 mg, 0.9; 42 mg, −1.0) or in the key secondary endpoint (MADRS Total time to first sustained response hazard ratio vs. placebo: 28 mg, 1.00; 42 mg, 0.93), likely due to a high placebo response. Both lumateperone doses were well tolerated, with low EPS risk and minimal changes in weight, prolactin, and cardiometabolic or endocrine parameters. While study efficacy objectives were not met, both doses of lumateperone were generally safe and well tolerated in patients with bipolar depression.

147

News (Medical) associated with Lumateperone Tosylate

14 Apr 2026

·www.fiercepharma.com

J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde

J&J is eying revenues of over $100 billion in 2026. As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the company’s new psoriasis pill is quickly taking shape and signaling its potential to become one of the drugmaker’s “largest products ever,” according to CEO Joaquin Duato.Protagonist Therapeutics-partnered Icotyde (icotrokinra) flew out of the gate upon its mid-March approval as the first targeted oral peptide designed to block the interleukin-23 (IL-23) receptor, presenting a new, once-daily alternative to the injectable biologics that make up much of the existing psoriasis market. J&J’s Icotyde launch took off the same day as its FDA approval came in, CEO Duato noted on the company’s first-quarter earnings conference call, with the company noting “strong demand” right away.Together with injectable immunology blockbuster Tremfya, Icotyde forms a key component of J&J’s “dual powerhouse” in immunology. Between the two, Tremfya presents a first-choice biologic for patients with moderate to severe plaque psoriasis and Icotyde is positioned as a systemic treatment, Duato explained. Tremfya, which has been the main contender to pick up the slack for Stelara’s declining sales, is expected to deliver more than $10 billion in peak yearly sales, according to the CEO. Stelara, meanwhile, is on a vastly different trajectory. The medicine is succumbing to biosimilar competition and served as a serious drag on the company’s innovative medicine division, which delivered $15.4 billion in first-quarter sales.The 7.4% operational sales growth seen across J&J’s innovative medicines category becomes 16.6% when excluding Stelara, Jennifer Taubert, worldwide chairman of innovative medicines at J&J, explained on the call. The double-digit growth seen when excluding Stelara gives the company confidence in its ambitious goal of generating more than $100 billion in annual sales. “It’s already happening today,” Duato said, referring to the performance needed to cross the $100 billion threshold. “It’s based on our product portfolio and pipeline, the strongest in our history.”J&J’s first-quarter innovative medicines growth was largely driven by its oncology and neuroscience sectors, which posted year-over-year operational sales increases of 17.8% and 29.3%, respectively.In oncology, the company’s revenues remain buoyed by its top-selling med Darzalex, the “gold standard” in multiple myeloma, Duato said. The drug has already bagged two new approvals so far this year, most recently with a combo nod alongside J&J’s Tecvayli in previously treated relapsed or refractory multiple myeloma in March. Neuroscience, meanwhile, is highlighted by a November expansion for J&J’s bipolar and schizophrenia med Caplyta as an add-on treatment for major depressive disorder. The drug is seeing “continued momentum” in that space, the company said in its investor presentation (PDF). While J&J’s immunology business saw $3.4 billion in worldwide sales during the period, Tremfya and its “share gains across all indications” couldn’t fully make up for continued biosimilar erosion to Stelara and new biosimilar rivals to older Simponi and Remicade, with the quarter yielding an 11.8% operational decline in immunology sales.Simponi should be up for more erosion this year, too, with biosimilars emerging in Europe over the first half of this year and potentially in the U.S. in the latter half of the year, the company noted. J&J on M&A As many of J&J’s peers participate in a recent resurgence of multibillion-dollar M&A deals, the company is content to rest on the major acquisitions it has already wrapped up in recent years. “We have been ahead of the curve in our investment in M&A,” Duato said, pointing to the company’s $14.6 billion purchase of Intra-Cellular Therapies last year and its $13.1 billion deal for Shockwave Medical in 2024. Instead, the drugmaker is looking to pour its investments into its new product launches and pipeline programs. Although it remains “optimistic” on business development, Duato made it clear that the company does “not depend on M&A” to fulfill its future revenue targets. For example, Icotyde is one area where J&J is “investing big,” Taubert said, with field teams and patient support services being built out to help patients “get on and be able to stay on” the pill. So far, some 1,500 patients have already had prescriptions written for the med, which can serve the large group of biologic-eligible patients who may be more hesitant to try an injectable therapy, according to Taubert. With the help of a “more pronounced impact” from its newly launched products, J&J lifted its 2026 sales outlook from the $100 billion to $101 billion range it projected in January, adding $300 million on each end.Adding on its medtech sales to its innovative medicines haul, the company collected a total of $24.1 billion over the first quarter, flexing 6.4% overall growth.

Drug ApprovalAcquisition

14 Apr 2026

·www.biospace.com

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS 4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIPULSE Pro in Europe with a new pulse sequence that is now 5 times faster, and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients Company announces planned Enterprise Business Review for December 8, 2026 NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.” Overall financial results Q1 ($ in Millions, except EPS) 2026 2025 % Change Reported Sales $24,062 $21,893 9.9% Net Earnings $5,235 $10,999 -52.4% EPS (diluted) $2.14 $4.54 -52.9% Q1 Non-GAAP* ($ in Millions, except EPS) 2026 2025 % Change Operational Sales 1,2 6.4% Adjusted Operational Sales 1,3 5.3% Adjusted Net Earnings 1,4 $6,614 $6,706 -1.4% Adjusted EPS (diluted) 1,4 $2.70 $2.77 -2.5% Free Cash Flow 5,6 ~$1,500 $3,379 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 6 First-quarter 2026 is estimated as of April 14, 2026 Note: values may have been rounded Regional sales results Q1 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 U.S. $13,330 $12,305 8.3% 8.3 - 6.2 International 10,732 9,588 11.9 3.9 8.0 4.0 Worldwide $24,062 $21,893 9.9% 6.4 3.5 5.3 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Segment sales results Q1 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 Innovative Medicine $15,426 $13,873 11.2% 7.4 3.8 5.6 MedTech 8,636 8,020 7.7 4.6 3.1 4.7 Worldwide $24,062 $21,893 9.9% 6.4 3.5 5.3 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded First-Quarter 2026 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 7.4%*, with net acquisitions and divestitures positively impacting growth by 1.8% primarily due to CAPLYTA. Growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (920) basis points impact from STELARA in Immunology, as well as IMBRUVICA in Oncology. MedTech MedTech worldwide operational sales grew 4.6%*, with divestitures negatively impacting growth by 0.1%. Growth was driven primarily by electrophysiology products, Abiomed, and Shockwave in Cardiovascular, as well as trauma in Orthopaedics. Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) April 2026 January 2026 Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point 5.6% – 6.6% / 6.1% 5.4% – 6.4% / 5.9% Operational Sales 2 / Mid-point Change vs. Prior Year / Mid-point $99.7B – $100.7B / $100.2B 5.9% – 6.9% / 6.4% $99.5B – $100.5B / $100.0B 5.7% – 6.7% / 6.2% Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point $100.3B – $101.3B / $100.8B 6.5% – 7.5% / 7.0% $100.0B – $101.0B / $100.5B 6.2% – 7.2% / 6.7% Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point $11.30 – $11.50 / $11.40 4.7% – 6.7% / 5.7% $11.28 – $11.48 / $11.38 4.5% – 6.5% / 5.5% Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point $11.45 – $11.65 / $11.55 6.1% – 8.1% / 7.1% $11.43 – $11.63 / $11.53 5.9% – 7.9% / 6.9% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: April 2026 = $1.17 and January 2026 = $1.17 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items Note: percentages may have been rounded Other modeling considerations will be provided on the webcast . Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at , or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and . Regulatory Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients Press Release Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line Press Release Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) Press Release Johnson & Johnson seeks FDA approval of IMAAVY (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) Press Release RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer Press Release FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month Press Release DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible Press Release Data Releases Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026 1 Press Release Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision 1 Press Release STEMI DTU Randomized Control Trial Demonstrates for the First Time that a Combination of Delayed Reperfusion and Left Ventricular Unloading Does Not Increase Myocardial Infarct Size Press Release ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety pro once‑daily pill for plaque psoriasis Press Release Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer Press Release Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer Press Release TREMFYA (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years Press Release RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer Press Release Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium Press Release Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA (apalutamide) versus darolutamide without docetaxel through 24 months Press Release Product Launch Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe 1 Press Release FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide Press Release Other Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania Press Release 1 Subsequent to the quarter Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations . About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results . Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results . Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , , investor.jnj.com , or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) FIRST QUARTER Percent Change 2026 2025 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. $ 8,871 8,092 9.6 % 9.6 - International 6,555 5,781 13.4 4.3 9.1 15,426 13,873 11.2 7.4 3.8 MedTech U.S. 4,459 4,213 5.9 5.9 - International 4,177 3,807 9.7 3.2 6.5 8,636 8,020 7.7 4.6 3.1 U.S. 13,330 12,305 8.3 8.3 - International 10,732 9,588 11.9 3.9 8.0 Worldwide $ 24,062 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) FIRST QUARTER Percent Change 2026 2025 Total Operations Currency Sales to customers by geographic area U.S. $ 13,330 12,305 8.3 % 8.3 - Europe 5,848 5,110 14.5 2.7 11.8 Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3 Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4 International 10,732 9,588 11.9 3.9 8.0 Worldwide $ 24,062 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency ONCOLOGY US $ 3,615 3,013 20.0% 20.0% - Intl 3,358 2,664 26.0% 15.3% 10.7% WW 6,973 5,678 22.8% 17.8% 5.0% DARZALEX US 2,208 1,829 20.7% 20.7% - Intl 1,756 1,409 24.7% 14.0% 10.7% WW 3,964 3,237 22.5% 17.8% 4.7% CARVYKTI US 433 318 36.2% 36.2% - Intl 164 51 * * * WW 597 369 62.1% 57.4% 4.7% TECVAYLI US 127 105 20.6% 20.6% - Intl 74 46 63.1% 52.1% 11.0% WW 202 151 33.5% 30.1% 3.4% TALVEY US 101 68 48.5% 48.5% - Intl 51 18 * * * WW 152 86 76.7% 72.8% 3.9% RYBREVANT / LAZCLUZE US 175 113 55.1% 55.1% - Intl 82 28 * * * WW 257 141 82.7% 80.5% 2.2% ERLEADA US 342 292 17.3% 17.3% - Intl 607 479 26.7% 15.5% 11.2% WW 949 771 23.1% 16.2% 6.9% IMBRUVICA US 143 235 (39.1)% (39.1)% - Intl 517 474 9.1% (1.4)% 10.5% WW 660 709 (6.9)% (13.9)% 7.0% OTHER ONCOLOGY (3) US 85 54 58.8% 58.8% - Intl 106 160 (33.9)% (36.3)% 2.4% WW 192 214 (10.6)% (12.5)% 1.9% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2026 2025 Reported Operational (1) Currency IMMUNOLOGY US $ 1,855 2,196 (15.5)% (15.5)% - Intl 1,524 1,510 0.9% (6.4)% 7.3% WW 3,380 3,707 (8.8)% (11.8)% 3.0% TREMFYA US 1,042 599 73.9% 73.9% - Intl 566 356 58.9% 46.8% 12.1% WW 1,608 956 68.3% 63.8% 4.5% SIMPONI / SIMPONI ARIA US 269 292 (7.8)% (7.8)% - Intl 378 366 3.0% (4.1)% 7.1% WW 647 659 (1.7)% (5.7)% 4.0% REMICADE US 269 314 (14.4)% (14.4)% - US Exports (4) 18 10 78.6% 78.6% - Intl 136 143 (4.8)% (10.5)% 5.7% WW 422 467 (9.5)% (11.2)% 1.7% STELARA US 220 981 (77.6)% (77.6)% - Intl 435 644 (32.4)% (37.7)% 5.3% WW 656 1,625 (59.7)% (61.7)% 2.0% OTHER IMMUNOLOGY US 38 1 * * - Intl 9 0 * * * WW 46 1 * * * NEUROSCIENCE US 1,494 968 54.3% 54.3% - Intl 681 679 0.3% (6.3)% 6.6% WW 2,175 1,647 32.0% 29.3% 2.7% SPRAVATO US 406 276 47.0% 47.0% - Intl 61 43 42.4% 28.7% 13.7% WW 468 320 46.4% 44.5% 1.9% CAPLYTA (5) US 270 - * * - Intl - - - - - WW 270 - * * - INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 758 625 21.2% 21.2% - Intl 280 277 1.1% (4.9)% 6.0% WW 1,038 903 15.0% 13.2% 1.8% CONCERTA / Methylphenidate US 22 38 (43.4)% (43.4)% - Intl 115 110 4.3% (0.6)% 4.9% WW 136 148 (8.0)% (11.7)% 3.7% OTHER NEUROSCIENCE US 38 28 32.6% 32.6% - Intl 224 248 (9.7)% (16.3)% 6.6% WW 262 277 (5.4)% (11.3)% 5.9% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2026 2025 Reported Operational (1) Currency PULMONARY HYPERTENSION (PH) US $ 831 744 11.7% 11.7% - Intl 304 281 8.2% 1.0% 7.2% WW 1,135 1,025 10.7% 8.7% 2.0% UPTRAVI US 385 365 5.4% 5.4% - Intl 98 86 14.3% 5.1% 9.2% WW 483 451 7.1% 5.4% 1.7% OPSUMIT / OPSYNVI US 433 363 19.3% 19.3% - Intl 172 159 8.7% 1.7% 7.0% WW 606 522 16.1% 14.0% 2.1% OTHER PULMONARY HYPERTENSION US 12 15 (21.1)% (21.1)% - Intl 34 37 (8.3)% (11.8)% 3.5% WW 46 52 (12.1)% (14.5)% 2.4% INFECTIOUS DISEASES (ID) US 342 315 8.6% 8.6% - Intl 547 487 12.2% 1.3% 10.9% WW 889 802 10.8% 4.1% 6.7% EDURANT / rilpivirine US 7 8 (13.1)% (13.1)% - Intl 402 350 14.8% 3.2% 11.6% WW 409 358 14.1% 2.8% 11.3% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 334 305 9.5% 9.5% - Intl 109 98 11.2% 0.7% 10.5% WW 443 403 10.0% 7.4% 2.6% OTHER INFECTIOUS DISEASES US 1 2 (56.9)% (56.9)% - Intl 36 39 (8.3)% (14.7)% 6.4% WW 37 41 (10.4)% (16.5)% 6.1% CARDIOVASCULAR / METABOLISM / OTHER (CVM) US 734 855 (14.2)% (14.2)% - Intl 142 158 (10.4)% (17.5)% 7.1% WW 876 1,013 (13.6)% (14.7)% 1.1% XARELTO US 642 690 (7.0)% (7.0)% - Intl - - - - - WW 642 690 (7.0)% (7.0)% - OTHER US 91 165 (44.5)% (44.5)% - Intl 142 158 (10.4)% (17.5)% 7.1% WW 233 323 (27.8)% (31.2)% 3.4% TOTAL PH, ID, CVM US 1,907 1,914 (0.4)% (0.4)% - Intl 993 926 7.1% (2.0)% 9.1% WW 2,899 2,840 2.1% (0.9)% 3.0% TOTAL INNOVATIVE MEDICINE US 8,871 8,092 9.6% 9.6% - Intl 6,555 5,781 13.4% 4.3% 9.1% WW $ 15,426 13,873 11.2% 7.4% 3.8% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency CARDIOVASCULAR US $ 1,399 1,261 10.9% 10.9% - Intl 978 842 16.1% 9.9% 6.2% WW 2,377 2,103 13.0% 10.5% 2.5% ELECTROPHYSIOLOGY US 736 684 7.6% 7.6% - Intl 753 638 18.0% 11.7% 6.3% WW 1,489 1,323 12.6% 9.5% 3.1% ABIOMED US 389 339 14.5% 14.5% - Intl 100 81 23.5% 13.9% 9.6% WW 488 420 16.3% 14.4% 1.9% SHOCKWAVE US 242 206 17.8% 17.8% - Intl 63 52 21.3% 19.3% 2.0% WW 305 258 18.5% 18.1% 0.4% OTHER CARDIOVASCULAR US 32 32 0.7% 0.7% - Intl 62 72 (13.4)% (17.5)% 4.1% WW 94 103 (9.1)% (11.9)% 2.8% SURGERY US 1,046 1,002 4.4% 4.4% - Intl 1,465 1,394 5.1% (1.1)% 6.2% WW 2,511 2,396 4.8% 1.2% 3.6% ADVANCED US 477 457 4.2% 4.2% - Intl 646 616 4.9% (1.0)% 5.9% WW 1,123 1,073 4.6% 1.2% 3.4% GENERAL US 569 544 4.5% 4.5% - Intl 819 778 5.2% (1.3)% 6.5% WW 1,388 1,323 4.9% 1.1% 3.8% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2026 2025 Reported Operational (1) Currency VISION US $ 579 566 2.4% 2.4% - Intl 785 713 10.1% 4.6% 5.5% WW 1,365 1,279 6.7% 3.6% 3.1% CONTACT LENSES / OTHER US 468 452 3.7% 3.7% - Intl 501 467 7.2% 1.7% 5.5% WW 969 919 5.5% 2.7% 2.8% SURGICAL US 111 114 (2.9)% (2.9)% - Intl 285 246 15.6% 10.1% 5.5% WW 396 361 9.7% 6.0% 3.7% ORTHOPAEDICS US 1,435 1,384 3.7% 3.7% - Intl 948 857 10.6% 2.4% 8.2% WW 2,383 2,241 6.3% 3.2% 3.1% HIPS US 277 263 5.2% 5.2% - Intl 159 146 8.9% 0.3% 8.6% WW 436 409 6.5% 3.5% 3.0% KNEES US 239 231 3.3% 3.3% - Intl 181 158 14.6% 6.5% 8.1% WW 420 389 7.9% 4.6% 3.3% TRAUMA US 532 502 6.1% 6.1% - Intl 301 270 11.4% 3.1% 8.3% WW 833 772 8.0% 5.0% 3.0% SPINE, SPORTS & OTHER US 387 388 (0.1)% (0.1)% - Intl 307 283 8.4% 0.7% 7.7% WW 694 671 3.5% 0.2% 3.3% TOTAL MEDTECH US 4,459 4,213 5.9% 5.9% - Intl 4,177 3,807 9.7% 3.2% 6.5% WW $ 8,636 8,020 7.7% 4.6% 3.1% Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of ZYTIGA which were previously disclosed separately (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 Contacts Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com Read full story here

08 Apr 2026

·www.fiercepharma.com

J&J's Tremfya retakes TV drug ad spending crown from AbbVie

It was a big drop for Novo Nordisk’s obesity drug Wegovy, which fell six places to ninth position. Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March.J&J spent $50.3 million on TV ads for its drug, according to data shared with Fierce Pharma Marketing from analysts at iSpot.tv. That’s up more than $10 million from February, when it ranked second in spending.Tremfya began the year in the top spot in January and is on an early course to rival the dominance of AbbVie, which has seen one of its blockbuster drugs claim the annual crown as the top TV spender for each of the past four years.AbbVie is still in the fight, however, taking the podium spots behind J&J with its immunology duo Skyrizi and Rinvoq, spending $42.1 million and $36.3 million, respectively. Rinvoq fell two spots after taking the top position in February.J&J is back again in fourth with its atypical antipsychotic drug Caplyta, with the drug up two spots from its February ranking and a $5.5 million increase in spending month over month.Eli Lilly’s obesity drug Zepbound comes in fifth, up two spots, with its highest level of spending going to its TV ad “Watch This: Head-to-Head,” which accounted for $12.3 million in March.Lilly returns in sixth alongside partner Boehringer Ingelheim with their diabetes and kidney disease drug Jardiance, while Sanofi and Regeneron’s megablockbuster immunology drug Dupixent takes seventh place.Lundbeck and Otsuka's neurology drug missed the top 10 in February but returned to eighth place in March.It was a big drop for Novo Nordisk’s obesity drug Wegovy, which fell six places to ninth, with spending sinking from $39.5 million in February to $13.5 million last month.Bristol Myers Squibb’s schizophrenia drug snuck into the final spot after not ranking in the top 10 in February.Check out the top 10 below, as compiled from analysts at iSpot.tv.1. Tremfya Movement: Up one spotWhat is it? Johnson & Johnson’s immunology drugEst. national linear TV ad spend: $50.3 million (up from $39.8 million in February)UC/Crohn’s disease: $33 millionPsoriasis: $5 millionPsoriatic Arthritis: $12.3 millionTop TV network by spend share of voice (SOV): ABC (17.69%)Top TV program by spend SOV: Men’s college basketball (5.34%)Number of spots: 11 (three psoriasis, five UC/Crohn’s disease, three psoriatic arthritis)Biggest-ticket ad: “Relentless Weed” (est. $15.3 million) 2. Skyrizi Movement: Up two spotsWhat is it? AbbVie’s immunology drug Est. national linear TV ad spend: $42.1 million (up from $37 million in February)UC/Crohn’s disease: $21.9 millionPsoriasis: $15.8 millionPsoriatic arthritis: $4.3 millionTop TV network by spend SOV: ABC (29.96%)Top TV program by spend SOV: The Oscars (12.16%)Number of spots: Seven (two psoriatic arthritis, three psoriasis, two UC/Crohn’s disease) Biggest-ticket ad: “In the Picture: Control Is Everything” (est. $11.8 million) 3. Rinvoq Movement: Down two spotsWhat is it? AbbVie’s JAK immunology drugEst. national linear TV ad spend: $36.3 million (down from $41 million in February)Top TV network by spend SOV: ABC (22.42%)Top TV program by spend SOV: Today (5.46%) Number of spots: Five (one arthritis, one UC/Crohn’s disease, three eczema)Biggest-ticket ad: “Another Day” (est. $13 million) 4. Caplyta Movement: Up two spotsWhat is it? Johnson & Johnson’s atypical antipsychotic drugEst. national linear TV ad spend: $23.4 million (up from $17.9 million in February)MDD: $23.2 millionBipolar: $154,000Top TV network by spend SOV: NBC (15.15%)Top TV program by spend SOV: Men’s college basketball (20.33%)Number of spots: Five (two bipolar, three MDD) Biggest-ticket ad: “Let in the Lyte: More of the Lyte” (est. $9.4 million) 5. ZepboundMovement: Up two spotsWhat is it? Eli Lilly’s GIP/GLP-1 agonist for obesityEst. national linear TV ad spend: $22.9 million (up from $17.2 million in February)Top TV network by spend SOV: ABC (32.12%)Top TV program by spend SOV: Men’s college basketball (43.14%) Number of spots: SevenBiggest-ticket ad: “Watch This: Head-to-Head” (est. $12.3 million) 6. JardianceMovement: Up three spotsWhat is it? Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drugEst. national linear TV ad spend: $20.8 million (up from $15 million in February)CKD: $13.4 millionDiabetes: $7.4 millionTop TV network by spend SOV: ABC (24.79%)Top TV program by spend SOV: ABC World News Tonight With David Muir (6.06%)Number of spots: Three (one CKD, two diabetes)Biggest-ticket ad: “Not So Fast: Garden” (est. $13.4 million) 7. DupixentMovement: Up one spotWhat is it? Sanofi and Regeneron’s immunology drugEst. national linear TV ad spend: $19.6 million (up from $15.5 million in February)Eczema: $15 millionAsthma: $4.6 millionGastrointestinal: $16,800Top TV network by spend SOV: ABC (30.44%)Top TV program by spend SOV: Men’s college basketball (39.70%) Number of spots: Eight (three asthma, four eczema, one gastrointestinal) Biggest-ticket ad: “Feel the Heal” (est. $9.6 million) 8. Rexulti (depression)Movement: Not listed last monthWhat is it? Lundbeck and Otsuka’s neurology drugEst. national linear TV ad spend: $16.5 million (up from $13 million in February)Top TV network by spend SOV: CBS (12.99%)Top TV program by spend SOV: NCIS (4.34%)Number of spots: Two Biggest-ticket ad: “Park and Arcade” (est. $14.9 million) 9. WegovyMovement: Down six spots What is it? Novo Nordisk’s obesity drug Est. national linear TV ad spend: $13.5 million (down from $39.5 million in February)Top TV network by spend SOV: ABC (38.16%)Top TV program by spend SOV: Men’s college basketball (56.05%)Number of spots: TwoBiggest-ticket ad: “A New Way” (est. $7.6 million) 10. CobenfyMovement: Not listed last monthWhat is it? Bristol Myers Squibb’s schizophrenia drugEst. national linear TV ad spend: $11.4 million (down from $12.6 million in February)Top TV network by spend SOV: CBS (25.77%)Top TV program by spend SOV: Men’s college basketball (27.69%)Number of spots: TwoBiggest-ticket ad: “Sagan’s Story” (est. $11.4 million)

100 Deals associated with Lumateperone Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
D11170	Lumateperone Tosylate	N05A	DB06077

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	United States	Johnson & Johnson	07 Nov 2025
Depressive Disorder, Major	United States	Intra-Cellular Therapies, Inc.	05 Nov 2025
Bipolar Disorder	United States	Intra-Cellular Therapies, Inc.	17 Dec 2021
Schizophrenia	United States	Intra-Cellular Therapies, Inc.	20 Dec 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Irritable Mood	Phase 3	United States	Intra-Cellular Therapies, Inc.	22 Nov 2024
Bipolar I disorder	Phase 3	United States	Intra-Cellular Therapies, Inc.	19 Jun 2024
Bipolar I disorder	Phase 3	Bulgaria	Intra-Cellular Therapies, Inc.	19 Jun 2024
Bipolar I disorder	Phase 3	Croatia	Intra-Cellular Therapies, Inc.	19 Jun 2024
Bipolar I disorder	Phase 3	India	Intra-Cellular Therapies, Inc.	19 Jun 2024
Bipolar I disorder	Phase 3	Serbia	Intra-Cellular Therapies, Inc.	19 Jun 2024
Mania	Phase 3	United States	Intra-Cellular Therapies, Inc.	19 Jun 2024
Mania	Phase 3	Bulgaria	Intra-Cellular Therapies, Inc.	19 Jun 2024
Mania	Phase 3	Croatia	Intra-Cellular Therapies, Inc.	19 Jun 2024
Mania	Phase 3	India	Intra-Cellular Therapies, Inc.	19 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04779177 (CTgov)	Phase 1	Schizoaffective disorder \| Schizophrenia	26	Lumateperone 42 mg	qaobsmoojc(lcjyprqkho) = jvakvffmuv nsepdseesa (yurnbqwltx, 11.21) View more	-	12 Nov 2025
NCT05061719 (CTgov)	Phase 3	Depressive Disorder, Major	812	Lumateperone	gwqgrqxlen = kihvwzzxeo oxqociimxk (bplynjjbqx, naobdampnv - amhobaqtna) View more	-	03 Nov 2025
NCT02600494 (CTgov)	Phase 3	Bipolar Disorder \| Bipolar II disorder \| Depressive Disorder, Major	554	Placebo	uctrdoyqgt(mxquwkbdgk) = urmuriqrme rnkprkojkx (aaqyxxtyov, 1.11) View more	-	03 Nov 2025
NCT01499563 (CTgov)	Phase 2	Schizophrenia	335	Placebo	jdsjdihtzb(grsyyvclcy) = wmbbgtwkmt ikiaiobqkl (rcvtmemaij, 1.7) View more	-	03 Oct 2025
NCT02469155 (CTgov)	Phase 3	Schizophrenia	696	ITI-007 (Lumateperone 14 mg (ITI-007 20 mg Tosylate))	culcolrcog(cdkdcfljyr) = zayxnjwuvv cxoublrgnj (lkbpbkwzuq, 1.27) View more	-	02 Oct 2025
				ITI-007 (Lumateperone 42 mg (ITI-007 60 mg Tosylate))	culcolrcog(cdkdcfljyr) = qommprqmao cxoublrgnj (lkbpbkwzuq, 1.23) View more
NCT02282761 (CTgov)	Phase 3	Schizophrenia	450	ITI-007 (Lumateperone 28 mg (ITI-007 40 mg Tosylate))	zvihgwcljc(kwkqsxungm) = rmzbcwzaza otzeoitbyo (mtnijyrrdj, 1.27) View more	-	02 Oct 2025
				ITI-007 (Lumateperone 42 mg (ITI-007 60 mg Tosylate))	zvihgwcljc(kwkqsxungm) = uylqhpxrax otzeoitbyo (mtnijyrrdj, 1.25) View more
NCT04985942 (CTgov)	Phase 3	Depressive Disorder, Major	485	Lumateperone (Lumateperone 42 mg)	mjfjvbiumm(niqaphybrh) = stfroqwkwd vsvkxdjrgx (ckdvqtmqrn, 0.54) View more	-	02 May 2025
				Placebo (Placebo)	mjfjvbiumm(niqaphybrh) = mwvjqrywca vsvkxdjrgx (ckdvqtmqrn, 0.53) View more
NCT05061706 (ITI-007-502, CTgov)	Phase 3	Depressive Disorder, Major	480	Lumateperone (Lumateperone 42 mg)	kzvetjmmes(ngzerweszf) = ilgkbnfqjf ntzwtuhwkg (mvtndwckmw, 0.56) View more	-	25 Mar 2025
				Placebo (Placebo)	kzvetjmmes(ngzerweszf) = dkcjtfurdh ntzwtuhwkg (mvtndwckmw, 0.54) View more
NCT04285515 (CTgov)	Phase 3	Bipolar Disorder \| Bipolar II disorder \| Depressive Disorder, Major	488	Lumateperone (Lumateperone 42mg)	neenbpjsgy(cwopfjivqv) = kvyfafnqvh qnhitxqbxy (nmszmbhyrr, 0.71) View more	-	19 Mar 2025
				Placebos (Placebo)	neenbpjsgy(cwopfjivqv) = nurqeiayis qnhitxqbxy (nmszmbhyrr, 0.70) View more
NCT04959032 (Company_Website) Manual	Phase 3	Schizophrenia	228	Lumateperone 42 mg	vngbpluawc(bzguafpvim) = rxievdtqyu qkbqdxzgjr (okskqpxpne ) Met	Positive	05 Nov 2024
				Placebo	vngbpluawc(bzguafpvim) = bcjrqfajfy qkbqdxzgjr (okskqpxpne ) Met

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis